• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cellectis S.A.

    1/8/26 4:35:05 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLLS alert in real time by email
    6-K 1 f6k_010826.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report: January 8, 2026

    Commission File Number: 001-36891

    Cellectis S.A.
    (Exact Name of registrant as specified in its charter)

    8, rue de la Croix Jarry
    75013 Paris, France
    +33 1 81 69 16 00

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]

     

     


    EXHIBIT INDEX

     

    Exhibit Title
       
    99.1 Press Release dated January 8, 2026


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Cellectis S.A.    
      (Registrant)
       
      
    Date: January 8, 2026     /s/ André Choulika    
      André Choulika
      Chief Executive Officer
      
    Get the next $CLLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLLS

    DatePrice TargetRatingAnalyst
    5/28/2026$9.00Overweight
    Barclays
    2/17/2026$7.00Buy
    Jefferies
    3/17/2023$6.00Buy
    Bryan Garnier
    5/18/2022$10.00Neutral → Outperform
    Robert W. Baird
    1/6/2022$16.00Overweight → Equal-Weight
    Wells Fargo
    11/30/2021$20.00Mkt Outperform
    JMP Securities
    11/8/2021Outperform → Mkt Perform
    William Blair
    10/8/2021$39.00 → $10.00Outperform → Neutral
    Baird
    More analyst ratings

    $CLLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Cellectis with a new price target

    Barclays initiated coverage of Cellectis with a rating of Overweight and set a new price target of $9.00

    5/28/26 8:55:44 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Cellectis with a new price target

    Jefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00

    2/17/26 7:48:16 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bryan Garnier initiated coverage on Cellectis with a new price target

    Bryan Garnier initiated coverage of Cellectis with a rating of Buy and set a new price target of $6.00

    3/17/23 9:01:09 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026

    NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice of meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/ About Cellectis     Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic

    5/20/26 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

    NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association (EHA) annual congress, on June 11-14, 2026, in Stockholm, Sweden. Lasme-cel – Oral Presentation The abstract reporting the full Phase 1 dataset from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T, in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL), has been

    5/12/26 9:30:00 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis Reports Financial Results for the First Quarter 2026

    Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial)  Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 dataset expected in Q4 2026 Innovation Preclinical data on TALE-based epigenetic editing, a non-DNA cutting approach, to be presented at ASGCT Servier (through Allogene): Interim pivotal data reported from the ALPHA3 trial of cema-cel (n=24) 58.3% of patients in the cema-cel arm achieved MRD negativity versus 16.7% in the observation armFavorable safety profile: no cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse EventsStudy accrual expected to be comple

    5/11/26 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    SEC Filings

    View All

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    5/20/26 4:35:03 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    5/12/26 9:35:06 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    5/11/26 4:35:08 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Leadership Updates

    Live Leadership Updates

    View All

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

    UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, 20241; cash runway projection into 2027Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company

    11/4/24 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

    NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation

    8/7/24 2:00:00 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Financials

    Live finance-specific insights

    View All

    Cellectis Reports Financial Results for the First Quarter 2026

    Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial)  Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 dataset expected in Q4 2026 Innovation Preclinical data on TALE-based epigenetic editing, a non-DNA cutting approach, to be presented at ASGCT Servier (through Allogene): Interim pivotal data reported from the ALPHA3 trial of cema-cel (n=24) 58.3% of patients in the cema-cel arm achieved MRD negativity versus 16.7% in the observation armFavorable safety profile: no cases of CRS, ICANS, GvHD, or Treatment-Related Serious Adverse EventsStudy accrual expected to be comple

    5/11/26 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis to Report First Quarter Financial Results on May 11, 2026

    NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2026 ending March 31, 2026 on Monday, May 11, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com About Cellectis Cellectis

    5/4/26 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2025 results and an update on business activities. Details for the call are

    3/12/26 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cellectis S.A. (Amendment)

    SC 13D/A - Cellectis S.A. (0001627281) (Subject)

    5/21/24 4:19:05 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

    SC 13G/A - Cellectis S.A. (0001627281) (Subject)

    2/14/24 5:07:22 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

    SC 13G/A - Cellectis S.A. (0001627281) (Subject)

    2/14/24 2:24:22 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care